ObsEva Reports Second Quarter 2018 Financial Results and Provides Business Update
August 08, 2018 01:00 ET
|
ObsEva SA
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Phase 2b EDELWEISS clinical trial...
ObsEva SA to Hold Second Quarter 2018 Financial Results and Business Update Call on August 8, 2018
July 31, 2018 01:30 ET
|
ObsEva SA
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Geneva, Switzerland and Boston, MA -...
ObsEva Expands Executive Team Hiring a Chief Commercial Officer
July 25, 2018 01:30 ET
|
ObsEva SA
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Geneva, Switzerland and Boston, MA -...
ObsEva SA to start trading today on the SIX Swiss Exchange
July 13, 2018 01:30 ET
|
ObsEva SA
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Trading of ObsEva's shares on SIX...
ObsEva SA Shares to Begin Trading on SIX Swiss Exchange
July 06, 2018 01:30 ET
|
ObsEva SA
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Listing of 45'381'252 registered...
ObsEva Announces Pricing of Follow-on Public Offering
June 20, 2018 02:49 ET
|
ObsEva SA
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Geneva, Switzerland and Boston, MA -...
ObsEva Announces Launch of Proposed Follow-on Public Offering
June 18, 2018 16:31 ET
|
ObsEva SA
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Geneva, Switzerland and Boston, MA -...
ObsEva SA Achieves Primary and Secondary Endpoints for EDELWEISS Phase 2b Clinical Trial of Linzagolix (OBE2109) in Women with Endometriosis
June 18, 2018 07:00 ET
|
ObsEva SA
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Partial suppression of estradiol...
ObsEva SA to Hold Investor Call to Announce Topline Results of the EDELWEISS Phase 2b Clinical Trial of Linzagolix (OBE2109) in Women with Endometriosis-Associated Pain on Monday June 18, 2018
June 15, 2018 16:00 ET
|
ObsEva SA
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Geneva, Switzerland and Boston, MA - June...
ObsEva SA to Seek SIX Share Listing
June 01, 2018 07:00 ET
|
ObsEva SA
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Geneva, Switzerland and Boston, MA...